DRONCIT TABLETS 50 MG

Summary of Product characteristics

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Droncit Tablets 50mg
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
MG PER TABLET
Praziquantel
50.0
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Tablet.
White round tablet scored on one side.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs and cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of adult tapeworms of dogs and cats.
The tablets are effective against both immature and mature forms of
adult tapeworms in both dogs and cats.
The product is a highly effective treatment against all the common
species of tapeworm infecting dogs and cats in the
United Kingdom and Ireland including_ Echinococcus granulosus_,_
Taenia ovis, Taenia pisiformis, Taenia multiceps, Taenia_
_hydatigena, Taenia taeniaeformis,_ and_ Dipylidium caninum._ Droncit
is also effective against_ Echinococcus multilocularis_
(see 4.4)
4.3 CONTRAINDICATIONS
Do not administer to dogs weighing less than 2.5 kg
Do not administer to unweaned puppies and kittens, as such animals are
rarely infected with tapeworms.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Fleas serve as intermediate hosts for one common type of
tapeworm-_Dipylidium caninum_. To avoid reinfection with
this parasite, flea control of the animal and its housing should be
carried out at the same time.
Unless flea control is
complete an infected flea population may survive: i.e. re-treatment of
the animal may be necessary.
As a precautionary measure to prevent establishment of_ Echinococcus
multilocularis_ in the UK and Ireland it is
recommended that all dogs entering the country be treated with
praziquantel.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
__
                                
                                Read the complete document